Buffalo Potash Corporation has finished drilling all five wells at its Disley Initial Production Module in Saskatchewan, including the final horizontal injector well. This completes the subsurface infrastructure needed for its patented Horizontal Line-Drive mining method, with each horizontal well achieving about 95% contact with the target clay seam. The company will soon begin well completion and brine circulation to prepare for potash production, targeting first output in the first quarter of 2027. This milestone positions Buffalo to move from drilling to operational phases, aiming to produce 125,000 tonnes per year initially, with plans for larger scale development.
Buffalo Potash's drilling completion is noted alongside Pluang's Basic Materials sector data. As of Sep 25, 2026 17:41 WIB, 23 of 38 priced Basic Materials stocks rose while 14 fell. Notable movers include Harmony Gold Mining Co. at USD 19.06 with a 2.86% increase and Icl Group Ltd at USD 5.32 with a 2.61% rise, both showing strong buy interest on Pluang.
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...
